who are at increased risk for HAV infection, including men who have sex with men (MSM) and persons who inject drugs (PWID). However, nationally representative estimates of vaccine coverage and immunity for this population are lacking. We used medical record and interview data from the 2009-2012 cycles of the Medical Monitoring Project, a nationally representative surveillance system of PLWH receiving HIV medical care in the United States, to estimate the prevalence of HAV immunity, defined as receipt of at least one dose of vaccine or laboratory documentation of anti-HAV antibodies, among 8695 MSM and PWID. Among HAV-nonimmune PLWH, we then examined factors associated with HAV vaccination during the 12-month retrospective observation period using Rao-Scott chi-square tests.
Introduction
Hepatitis A virus (HAV) infection is typically self-limited to acute liver inflammation and does not result in chronic illness (World Health Organization, 2015) . However, HAV infection among persons living with HIV (PLWH) may lead to more severe illness and prolonged HAV viremia and shedding, which can lead to a longer infectious period (Ida et al., 2002) . The most common non-AIDS related cause of death among PLWH in the United States is liver disease (Palella Jr. et al., 2006 hepatitis B virus infection and one-quarter with hepatitis C virus (HCV) infection, (Thio, 2009; Alter, 2006; Thio et al., 2002; Centers for Disease Control and Prevention, 2017) which can increase the risk of fulminant hepatitis and death from HAV infection (Vento et al., 1998) . To reduce morbidity and mortality among PLWH with liver disease, HAV vaccination is a necessary and critical intervention. The Department of Health and Human Services' Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 2018) and the HIV Medicine Association's Primary Care Guidelines for the Management of Persons Infected with HIV (Aberg et al., 2014) recommend HAV vaccination for HIV-infected persons who inject drugs (PWID) and men who have sex with men (MSM).
Nationally representative estimates of HAV immunity and vaccine coverage for MSM and PWID living with HIV are lacking (World Health Organization, 2015; Centers for Disease Control and Prevention, 2016a) . In this analysis we sought to estimate the prevalence of HAV vaccination, or anti-HAV antibodies conferring immunity, and to examine factors associated with HAV vaccination of non-immune PLWH for whom vaccination is recommended.
Methods

Sampling and data collection
We used data from the 2009-2012 cycles of the Medical Monitoring Project (MMP), a cross-sectional, complex sample survey designed to produce nationally representative estimates of behavioral and clinical outcomes among adults receiving outpatient HIV medical care in the United States and Puerto Rico (Centers for Disease Control and Prevention, 2016b) . Further details on MMP's methods are described elsewhere (Centers for Disease Control and Prevention, 2016b) . Briefly, during 2009-2012, MMP used a three-stage probability-proportionalto-size sampling method. First, states and territories were sampled, followed by outpatient facilities in those sampled states and territories providing HIV care, and finally, PLWH ages 18 years or older who had received medical care at participating facilities in those states and territories between January and April during the cycle year were sampled. All sampled states and territories participated. The facility response rates ranged from 76% to 85% and the patient response rates ranged from 49% to 55%. Data used in the analysis were collected from June 1, 2009 through May 31, 2013 via face-to-face or telephone interviews and medical record abstraction. Data were weighted for unequal selection probabilities and nonresponse. CDC determined the MMP to be a public health surveillance activity used for disease control, program, or policy purposes; however, some local institutional review board approval was obtained at participating states, territories, and facilities when required (Centers for Disease Control and Prevention, 2010) . Informed consent was obtained from all interviewed participants.
Measures
HAV immunity was defined as having received at least one dose of an HAV vaccine or laboratory documentation of any positive detection of HAV antibodies (IgM, IgG, or total) in the patient's medical record. We defined patients not meeting these criteria as nonimmune and candidates to initiate HAV vaccination. Clinical characteristics included time since HIV diagnosis (categorized as < 5 years vs ≥5 years); prescription of antiretroviral therapy (ART) in the past 12 months; and sustained viral suppression (all HIV RNA test result during the surveillance period undetectable or < 200 copies/mL). Sociodemographic characteristics included being a PWID or an MSM; race/ethnicity (black/African American, non-Hispanic/Latino [black]; white nonHispanic/Latino [white]; Hispanic/Latino; and other races/ethnicities); age; gender (male or female); educational attainment (< high school, high school or equivalent; or > high school); and whether the primary HIV care facility received funding from the Ryan White HIV/AIDS Program (RWHAP). The time reference for all measured variables were 12 months prior to the interview.
Among MSM and PWID without documentation of immunity at baseline, we estimated the percentage of patient vaccinated during the 12-month retrospective observation period. Twenty-seven MSM or PWID who had a positive HAV antibody result and lacked HAV vaccination documentation during the 12-month retrospective observation period were excluded from this analysis because they had developed natural immunity and were no longer candidates for vaccination. MSM and PWID were combined for this portion of the analysis due to the small number of PWID, many of whom were also MSM.
Data analyses
The analytic dataset included records of 18,095 participants, of whom 8695 were MSM or PWID. We analyzed data across two time intervals: 1) from the date of HIV diagnosis until baseline at one year prior to the patient interview date; 2) from baseline through the patient interview date (a 12-month retrospective observation period) (Fig. 1) . We computed frequencies, weighted percentages, and 95% confidence intervals (CI) to estimate the prevalence of HAV immunity at baseline among PLWH who were MSM, PWID, and MSM who were also PWID.
We computed frequencies and weighted percentages with their 95% confidence intervals (CI) to estimate the prevalence of HAV immunity at baseline among PLWH who were MSM, PWID, and MSM who are also PWID. We then estimated the overall prevalence of HAV immunity documented between the initiation of HIV medical care and baseline, and from baseline through the interview date. Finally, we assessed associations of vaccination during the 12-month retrospective observation period between baseline and the interview date among previously nonimmune patients with sociodemographic, behavioral, and clinical characteristics using the Rao-Scott chi-square test. Bivariate associations of patient characteristics with recent HAV vaccination were considered significant at P < 0.05. Analyses were completed using SAS 9.3 (SAS Institute, Cary, NC).
Results
Among persons receiving HIV medical care in the United States during June 2009 through May 2013, 48% were MSM, and 2% were PWID. Among MSM and PWID, the prevalence of HAV immunity at baseline was 58%. Specifically, the prevalence of HAV immunity among MSM was 57%, 60% among PWID, and 68% among MSM who were also PWID. Among MSM and PWID without documented immunity at baseline, 10% were vaccinated for HAV during the following 12 months. By the end of this observation period, 64% of MSM and PWID had documented immunity. Specifically, 64% of MSM had documented immunity, as did 65% of PWID, and 76% of MSM who were also PWID (Data not shown). Table 1 displays sociodemographic and clinical characteristics of all US HIV patients and HIV patients who are MSM or PWID, stratified by hepatitis A immune status. Vaccination during the 12-month retrospective observation period was more common among younger persons, non-Hispanic blacks, and those born in the United States. Those more recently diagnosed with HIV, having a detectable HIV viral load test, and receiving care at a Ryan White HIV/AIDS Program funded facility were significantly more likely to be vaccinated during the 12-month retrospective observation period (Table 2 ).
Discussion
In the general population, the incidence of HAV in the United States has dropped by 95% since the introduction of the HAV vaccine in 1995 (Centers for Disease Control and Prevention, 2016a). However, between 2000 and 2010, seroprevalence of HAV antibodies plateaued among persons aged 20-39 years and decreased among adults ≥40 (Murphy et al., 2016) . Past studies have found that HAV antibody seroprevalence among PLWH ranged from 40 to 83% in MSM and from 62 to 86% in PWID (Lin et al., 2017) . Although precise data are lacking, vaccine coverage among MSM and PWID in the general population appears to be low (Cotter et al., 2003) .Our study was the first to examine HAV vaccination and immunity among people with increased risk for infection receiving HIV care at different types of facilities in both high and low prevalence areas, representative of the diversity of US HIV patients. In addition, our sampling and weighting methods permit inference to all US HIV patients at increased risk for HAV. 
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There are several plausible reasons for the low prevalence of HAV vaccination among patients receiving HIV medical care, including cost and lack of insurance reimbursement. The National Academy of Medicine reports substantial variation in vaccine coverage and payment policies among public and private insurers (Institute of Medicine Committee on Immunization Finance Policies and Practices, 2000). In addition, adults are not included in state systems for universal vaccine purchase and distribution. The RWHAP allows the use of funds to purchase and administer vaccines (Health Resources and Services Administration, 2017). However, the extent to which funds are used for this purpose is not known and at least one-quarter of HIV patients receive care at facilities that do not receive RWHAP funding (Weiser et al., 2015) . Increasing vaccine coverage for PLWH could increase hepatitis A vaccination and reduce morbidity.
Providers might not vaccinate because they are unaware of vaccination guidelines or because they underestimate the risk and severity of HAV infection (Tenner et al., 2012; Nelson et al., 2017) . The Advisory Committee on Immunization Practices has recommended hepatitis A vaccination of MSM and PWID since 1996 (Centers for Disease Control and Prevention, 1996) . Since 1999, the US Public Health Service and the Infectious Disease Society of America have recommended vaccination all PLWH who are MSM or PWID (Centers for Disease Control and Prevention, 1999). Additional efforts to disseminate these guidelines are needed. Finally, concerns about vaccine safety, and patient unwillingness might be barriers to wider vaccination (Tenner et al., 2012) . Clear messaging about the safety and effectiveness of hepatitis A vaccination is needed.
Study limitations
This study was subject to several limitations. First, because not all unvaccinated patients were tested for anti-HAV antibodies, our estimate of immunity may have been low. Second, because administration of HAV vaccine, particularly a single dose, is not always immunogenic, our estimate of the prevalence of immunity based on documented vaccination, may have been elevated. Nevertheless, more than a third of patients had a missed opportunity to at least begin the process of vaccination. Lastly, this analysis was limited to persons receiving HIV medical care, so our findings should not be generalized to all PLWH.
Conclusions
In conclusion, over a third of persons receiving HIV care in the United States had missed opportunities for HAV vaccination. Increased coverage for hepatitis A vaccination, wider dissemination of clinical guidelines, and clear messaging about the safety and effectiveness of 
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